USP <711> - Dissolution

What it says

General Chapter <711> describes dissolution testing apparatus and methodology for solid oral dosage forms, specifying standardised apparatus types, testing conditions and acceptance criteria used to assess how a drug product releases its active ingredient over time under controlled conditions.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Dissolution testing serves as both a quality control release test and, often, a surrogate indicator of in vivo bioavailability, connecting a relatively simple in vitro laboratory test to real-world clinical performance expectations.
• Apparatus qualification, calibration and performance verification are critical to generating meaningful dissolution data, since even small deviations in apparatus operating parameters such as rotation speed or vessel positioning can meaningfully affect results.
• Dissolution method development and validation, connecting back to ICH Q2(R2) principles, must demonstrate the method is discriminating, meaning it can actually detect meaningful differences in product performance rather than passing essentially any batch regardless of true quality variation.

What inspectors look for

• Whether dissolution apparatus qualification and ongoing performance verification, including mechanical calibration, is current and documented.
• Whether the dissolution method used has been demonstrated to be genuinely discriminating for the specific product, capable of detecting meaningful quality differences.
• Whether dissolution results outside expected ranges are investigated with appropriate root cause rigor, consistent with general OOS investigation principles.

Related regulations